- 中国科技论文统计源期刊
- 中国科技核心期刊
- 中国高校优秀期刊
- 安徽省优秀科技期刊
| Citation: |
LI Hongxia, ZENG Huan, LU Yuli. Relationship of serum circRNA-AKT1 and clinicopathological characteristics in cervical cancer patients and its prognostic value analysis[J]. Journal of Bengbu Medical University, 2024, 49(10): 1335-1339. DOI: 10.13898/j.cnki.issn.1000-2200.2024.10.014
|
To analyze the relationship of serum circRNA-AKT1 and clinicopathological characteristics in cervical cancer patients and its prognostic value.
General data and serum samples were collected from 64 patients with cervical cancer (cervical cancer group), 43 patients with cervical intraepithelial neoplasia (CIN) (CIN group), 22 patients with uterine fibroids (uterine fibroids group), and 81 healthy subjects (control group).The qRT-PCR was used to determine the serum circRNA-AKT1 level of the subjects and the serum circRNA-AKT1 levels were compared among the groups; the ROC curve was performed to evaluate the diagnostic efficacy of circRNA-AKT1 in cervical cancer; the correlation between serum circRNA-AKT1 level and clinicopathological characteristics of cervical cancer patients was analyzed; KM survival curve was utilized to analyze the relationship between serum circRNA-AKT1 and the prognosis of cervical cancer patients; Cox regression was used to analyze the risk factors for poor prognosis in cervical cancer patients.
Compared with patients in the control group, the serum circRNA-AKT1 levels of patients in the CIN group and cervical cancer group were increased (P < 0.05);compared with patients in the uterine fibroids group, the serum circRNA-AKT1 levels of patients in the CIN group and cervical cancer group were increased (P < 0.05);compared with patients in the CIN group, the serum circRNA-AKT1 levels of patients in the cervical cancer group were increased (P < 0.05).ROC curve results showed that the AUC for serum circRNA-AKT1 level to diagnosis cervical cancer was 0.931.CircRNA-AKT1 level in serum of cervical cancer patients was showed not to be related to the age, menopausal status, tumor size, or pathological type (P>0.05).Compared with FIGO stage Ⅰ to Ⅱ patients, stage Ⅲ to Ⅳ patients showed elevated proportion of patients with high serum circRNA-AKT1 (P < 0.05);compared with patients without lymph node metastasis, patients with lymph node metastasis exhibited increased proportion of patients with high serum circRNA-AKT1 (P < 0.05).The KM curve showed that the 3-year cumulative survival rate of patients in the circRNA-AKT1 high-expression group (56.4%) was lower than that of patients in the circRNA-AKT1 low-expression group (76.0%), and the difference was statistically significant (χ2=4.01, P < 0.05).Multivariate Cox regression analysis showed that lymph node metastasis, FIGO stage, and circRNA-AKT1 level were risk factors for poor prognosis of cervical cancer patients (P < 0.05).
The circRNA-AKT1 is highly expressed in the serum of patients with cervical cancer and is related to lymph node metastasis, clinical stage and patient prognosis.Serum circRNA-AKT1 can serve as an important auxiliary indicator for predicting the prognosis of patients with cervical cancer.
| [1] |
刘湛秋, 何玉, 许驰, 等. 宫颈细胞学p16~(INK4a)蛋白检测联合细胞学检测在宫颈癌筛查中的价值[J]. 蚌埠医学院学报, 2021, 46(4): 479. doi: 10.13898/j.cnki.issn.1000-2200.2021.04.014
|
| [2] |
霍会蚕, 王如意, 李艳云, 等. 高危型HPV感染及CALCA基因启动子甲基化在宫颈病变检测中的临床价值[J]. 中华医院感染学杂志, 2021, 31(17): 2628.
|
| [3] |
LIU T, YE P, YE Y, et al. Circular RNA hsa_circRNA_002178 silencing retards breast cancer progression via microRNA-328-3p-mediated inhibition of COL1A1[J]. J Cell Mol Med, 2020, 24(3): 2189. doi: 10.1111/jcmm.14875
|
| [4] |
XU H, LIU Y, CHENG P, et al. CircRNA_0000392 promotes colorectal cancer progression through the miR-193a-5p/PIK3R3/AKT axis[J]. J Exp Clin Cancer Res, 2020, 39(1): 283. doi: 10.1186/s13046-020-01799-1
|
| [5] |
OU R, MO L, TANG H, et al. CircRNA-AKT1 sequesters miR-942-5p to upregulate AKT1 and promote cervical cancer progression[J]. Mol Ther Nucleic Acids, 2020, 20: 308. doi: 10.1016/j.omtn.2020.01.003
|
| [6] |
YU L, WEI J, LIU P. Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer[J]. Semin Cancer Biol, 2022, ,85: 69. doi: 10.1016/j.semcancer.2021.06.019
|
| [7] |
徐聪聪, 陈浩. PI3K/Akt/mTOR信号通路在皮肤鳞状细胞癌中的研究进展[J]. 中华皮肤科杂志, 2020, 55(3): 264.
|
| [8] |
CHEN Q, LI L, LIU X, et al. Hexokinases 2 promoted cell motility and distant metastasis by elevating fibronectin through Akt1/p-Akt1 in cervical cancer cells[J]. Cancer Cell Int, 2021, 21(1): 600. doi: 10.1186/s12935-021-02312-0
|
| [9] |
刘小叶, 周建斌, 李婷, 等. Akt1在环氧合酶-2抑制剂抑制宫颈癌Hela细胞增殖中的作用[J]. 中南医学科学杂志, 2014, 28(4): 359.
|
| [10] |
CHEN X, SUN H, ZHAO Y, et al. CircRNA circ_0004370 promotes cell proliferation, migration, and invasion and inhibits cell apoptosis of esophageal cancer via miR-1301-3p/COL1A1 axis[J]. Open Med(wars), 2021, 16(1): 104. doi: 10.1515/med-2021-0001
|
| [11] |
王海燕, 孙宝琳, 穆庆芬, 等. 环状RNA-100269在宫颈癌中的表达及对细胞生物学特征的影响[J]. 中国妇产科临床杂志, 2021, 22(3): 258.
|
| [12] |
申倩倩, 王焱, 王晓, 等. 沉默环状RNA hsa_circ_0011021表达对宫颈癌细胞增殖迁移及侵袭的影响[J]. 西部医学, 2019, 31(9): 1339.
|
| [13] |
WU S, LIU S, SONG H, et al. Circular RNA HIPK3 plays a carcinogenic role in cervical cancer progression via regulating miR-485-3p/FGF2 axis[J]. J Investig Med, 2020, 69(3): 768.
|
| [14] |
ZHU Q, ZHAN D, ZHU P, et al. CircAKT1 acts as a sponge of miR-338-3p to facilitate clear cell renal cell carcinoma progression by up-regulating CAV1[J]. Biochem Biophys Res Commun, 2020, 532(4): 584. doi: 10.1016/j.bbrc.2020.08.081
|
| [15] |
张亚珍, 宋杰峰, 吴煌福, 等. miR-324-3p靶向AKT1调控乳腺癌细胞放射增敏性的机制研究[J]. 中国临床研究, 2020, 33(7): 879.
|
| [16] |
郭锡春, 陈景华, 高如俊, 等. 姜黄素通过miR-29b/KDM2A介导PI3K/AKT信号通路抑制宫颈癌细胞的侵袭和迁移[J]. 中国药学: 英文版, 2020, 29(6): 398.
|
| [17] |
吉洁, 马志君, 曹振东, 等. 白茅苷抑制AKT的活化对宫颈癌细胞增殖, 凋亡和线粒体膜电位的影响[J]. 中国免疫学杂志, 2020, 36(3): 338. doi: 10.3969/j.issn.1000-484X.2020.03.015
|
| [18] |
刘晓娟, 谢双双, 张晶, 等. LINC00665通过靶向miR-138/AKT1促进Hela细胞增殖和抑制凋亡的机制研究[J]. 中国实验诊断学, 2021, 25(5): 750. doi: 10.3969/j.issn.1007-4287.2021.05.032
|
| 1. |
包雪梅，张剑. 恩替卡韦治疗慢性乙型肝炎病毒感染患者临床疗效分析. International Infections Diseases(Electronic Edition). 2020(01): 106 .
| |
| 2. |
杨轲勇. 恩替卡韦对慢性乙型肝炎病毒感染患者HBeAg、HBV-DNA、ALT水平的影响. 临床医学工程. 2020(05): 639-640 .
| |
| 3. |
夏培华，刘丽凤，于姜标. 苦参素联合抗病毒治疗慢性乙型肝炎肝硬化的效果观察. 中国药物与临床. 2020(05): 762-764 .
| |
| 4. |
崔璐，蔡秋娥，王淼，王素华. 妊娠期乙肝患者服用替诺福韦后阻断宫内乙肝病毒传播疗效及安全性. 中国计划生育学杂志. 2020(10): 1658-1660 .
| |
| 5. |
黄修伙，罗贤鑫，陈兴. 恩替卡韦联合甘草酸二铵治疗慢性乙型肝炎的临床效果. 中国当代医药. 2020(31): 53-55 .
| |
| 6. |
庄海珍，林丽华. 双环醇片联合恩替卡韦对慢性乙型肝炎患者血清乙型肝炎病毒表面抗原丙氨酸转氨酶水平的影响. 中国药物与临床. 2019(06): 963-966 .
| |
| 7. |
刘飞飞，舒福丽，邬碧波. 恩替卡韦治疗慢性乙型肝炎病毒感染对患者HBV-DNA水平的影响及安全性观察. 临床合理用药杂志. 2019(19): 53-54 .
| |
| 8. |
俞建家. 恩替卡韦治疗慢性乙型肝炎病毒感染患者临床疗效研究. 实用心脑肺血管病杂志. 2019(S2): 93-94 .
| |
| 9. |
陈晨楠. 恩替卡韦治疗HBeAg阴性代偿期慢性乙型肝炎肝硬化的临床效果观察. 现代医学与健康研究电子杂志. 2018(14): 38 .
| |
| 10. |
梁洁玲，唐岚. 恩替卡韦对乙型肝炎病毒感染患者的临床疗效及其对肝功能的改善和HBeAg转阴的影响. 抗感染药学. 2018(09): 1587-1589 .
| |
| 11. |
曹素珍. 恩替卡韦抗乙型肝炎病毒应答不佳患者挽救方案的效果对比分析. 临床医药文献电子杂志. 2018(90): 60+62 .
|
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: